

SAFETY DATA SHEET



1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material	ADARTREL TABLETS
Synonym(s)	ADARTREL 0.25 MG TABLETS * ADARTREL 0.5 MG TABLETS * ADARTREL 2 MG TABLETS * REPREVE TABLETS * ROPINIROLE HYDROCHLORIDE, FORMULATED PRODUCT
Company Name	<p>GlaxoSmithKline, Corporate Environment, Health & Safety 980 Great West Road Brentford, Middlesex TW8 9GS UK</p> <p>UK General Information: +44-20-8047-5000 Transport Emergency (EU) +44-1865-407333 Medical Emergency +1-612-221-3999, Ext 221 Information and Advice: US number, available 24 hours Multi-language response</p> <p>GlaxoSmithKline, Corporate Environment, Health & Safety One Franklin Plaza, 200 N 16th Street Philadelphia, PA 19102-1225 US</p> <p>US General Information: +1-888-825-5249 Transport Emergency (non EU) +1-703-527-3887 US number, available 24 hours Multi-language response</p>

* 2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS #	Percent	EC-No.
ROPINIROLE HYDROCHLORIDE	91374-20-8	4	
Other components below reportable levels		96	

3. HAZARDS IDENTIFICATION

Fire and Explosion	Expected to be non-combustible.
Health	Caution - Pharmaceutical agent. Exposure might occur via skin; eyes; ingestion. Health effects information is based on hazards of components.
Environment	No information is available about the potential of this product to produce adverse environmental effects.

4. FIRST-AID MEASURES

Ingestion	Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
Inhalation	Physical form suggests that risk of inhalation exposure is negligible.
Skin Contact	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.

Material ADARTREL TABLETS

Eye Contact Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment Medical treatment in cases of overexposure should be treated as an overdose of D2-dopamine agonist. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

Medical Conditions Caused or Aggravated by Exposure None for occupational exposure.

Antidotes No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards Not expected for the product, although the packaging is combustible.

Extinguishing Media Water or foam extinguishers are recommended. Carbon dioxide or dry powder extinguishers may be ineffective.

Special Firefighting Procedures For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.

Hazardous Combustion Products Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Clean-up Methods Collect and place it in a suitable, properly labelled container for recovery or disposal.

Decontamination Procedures No specific decontamination or detoxification procedures have been identified for this product.

7. HANDLING AND STORAGE

HANDLING

General Requirements Avoid breaking or crushing tablets.

STORAGE

No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

INGREDIENT	ROPINIROLE HYDROCHLORIDE	
GSK Occupational Hazard Category	3	
GSK Occupational Exposure Limit	20 MCG/M3 (8 HR TWA)	REPRODUCTIVE HAZARD

ENGINEERING CONTROLS

Containment Open handling may result in overexposure.

Ventilation Local exhaust ventilation (LEV) should be used in conjunction with other control measures as a means of removing material incidentally released.

Administrative Entry to the working area should be controlled. Only authorised personnel may enter the working area.

Other Equipment or Procedures None required for normal handling. Wear appropriate clothing to avoid skin contact.

Material ADARTREL TABLETS

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Physical Form Tablet.

10. STABILITY AND REACTIVITY

Stability This product is expected to be stable.

Conditions to Avoid None for normal handling of this product.

11. TOXICOLOGY INFORMATION

Pharmacological Effects This product contains active ingredient(s) with the following activity: a dopaminergic agonist.

Target Organ Effects Adverse effects might occur in the following organ(s) following overexposure: cardiovascular system.

Routes of Exposure

Oral Toxicity Not expected to be toxic following ingestion.

Inhalation Toxicity No studies have been conducted.

Skin Effects Irritation is not expected following direct contact.

Eye Effects Irritation is not expected following direct contact with eyes.

Sensitisation Sensitisation (allergic skin reaction) is not expected.

Genetic Toxicity Not expected to be genotoxic under occupational exposure conditions.

Carcinogenicity No components are listed as carcinogens by GSK, IARC, NTP or US OSHA.

Reproductive Effects Not expected to produce adverse effects on fertility or development under occupational exposure conditions. Contains components which have been classified as: Known or presumed to affect the quantity and quality of breast milk in humans.

12. ECOLOGICAL INFORMATION

Summary This material contains an active pharmaceutical ingredient that has been tested and which may be harmful if released directly to the environment. Consult the MSDS of the active ingredient for specific information about potential environmental effects. Appropriate precautions should be taken to limit release of this material to the environment. Local regulations and procedures should be consulted prior to environmental release.

Specific information on the active pharmaceutical ingredient is provided below.

ECOTOXICITY

Aquatic

Activated Sludge Respiration This material contains an active pharmaceutical ingredient that is not toxic to activated sludge microorganisms.
IC50: 500 mg/L, 3 Hours, Residential sludge

Microtox Microtox is a general toxicity test which utilizes a sensitive marine photo bacteria as the test species. This material contains an active pharmaceutical ingredient that is not toxic to these microorganisms.

EC50: 362 mg/L, 15 Minutes

Algal This material contains an active pharmaceutical ingredient that is harmful to algae.

IC50: 29.3 mg/L, 72 Hours, Selenastrum capricornutum, green algae

NOEC: 8.8 mg/L, 72 Hours, Selenastrum capricornutum, green algae

Daphnid This material contains an active pharmaceutical ingredient that is harmful to daphnids.

EC50: 41.1 mg/L, 48 Hours, Daphnia magna, Static test

NOEC: 4.4 mg/L, 48 Hours, Daphnia magna, Static test

Material ADARTREL TABLETS

	Chronic EC50:	7.7 mg/L, 8 Days, Ceriodaphnia dubia, 7 day static renewal
	Chronic LOEC:	10 mg/l, 8 Days, Ceriodaphnia dubia
	Chronic NOEC:	3.2 mg/L, 8 Days, Ceriodaphnia dubia
Fish	This material contains an active pharmaceutical ingredient that is harmful to fish.	
	Adult Lepomis macrochirus, bluegill sunfish	
	EC50:	11 mg/L, 96 Hours, Static test
	Adult Lepomis macrochirus, bluegill sunfish	
	NOEC:	3.7 mg/L, 96 Hours, Static test
MOBILITY		
Solubility	This material contains an active pharmaceutical ingredient that for environmental fate predictions has solubility in water.	
Volatility	This material contains an active pharmaceutical ingredient that will not readily enter into air from water.	
	Henry's Law Constant	5.67E-07 atm m ³ /mol, Calculated
Adsorption	This material contains an active pharmaceutical ingredient that is not likely to adsorb to sludge or biomass if released directly to the environment.	
	Soil Sediment Sorption (log K _{oc}):	0.74, Calculated at pH 7
	Sludge Biomass Distribution Coefficient (log K _d):	1.92 Measured
Partitioning	This material contains an active pharmaceutical ingredient with octanol/water partition coefficient data that suggests that for environmental fate predictions the active pharmaceutical ingredient will not have the tendency to distribute into fats.	
PERSISTENCE/DEGRADATION		
Hydrolysis	This material contains an active pharmaceutical ingredient that has been shown to be chemically unstable in water. Hydrolysis may be a significant depletion mechanism.	
	Half-Life, Neutral:	163 Days, Measured
Photolysis	This material contains an active pharmaceutical ingredient that has been shown to be chemically stable in water when exposed to light. Aqueous photolysis is unlikely to be a significant depletion mechanism.	
	Half-Life, Aqueous:	433 to 13700 Days, Measured
Biodegradation	This material contains an active pharmaceutical ingredient that is not readily biodegradable (as defined by 1993 OECD Testing Guidelines). It may persist in the environment.	
Bioaccumulation	This material contains an active pharmaceutical ingredient that will not have a tendency to bioaccumulate in the food chain.	
	Bioconcentration Factor:	1 Estimated

13. DISPOSAL CONSIDERATIONS

Disposal Recommendations	Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.
Regulatory Requirements	Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling

Transport Information	Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes.
------------------------------	---

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

EU Classification and Labelling

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

US OSHA Standard (29 CFR Part 1910.1200)

Classification This dosage form is exempt from the requirements of the OSHA Hazard Communication Standard.

Other US Regulations

TSCA Status Exempt

16. OTHER INFORMATION

References GSK Hazard Determination

SDS Version Number 3

SDS Sections Updated

Sections

COMPOSITION / INFORMATION ON INGREDIENTS

Subsections

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.